anastrozole has been researched along with Recrudescence in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer." | 9.16 | FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. ( Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F, 2012) |
| "Whether anastrozole has superior effects to tamoxifen for breast cancer remains controversial." | 8.95 | A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. ( Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y, 2017) |
| "We report a case of recurrent hormone receptor-positive breast cancer with brain metastases that showed good response to vinorelbine(VNR)and anastrozole(ANA)." | 7.78 | [A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies]. ( Hikino, H; Koike, M; Mukai, T; Murata, Y, 2012) |
| "To compare the effect of therapy with anastrozole versus a combination of fulvestrant and anastrozole in women in first relapse of endocrine-responsive breast cancer." | 5.16 | FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. ( Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F, 2012) |
| "6 mg subcutaneously every 28 days) in combination with anastrozole or tamoxifen with or without zoledronic acid (4 mg intravenously every 6 months) in premenopausal women with endocrine-responsive breast cancer." | 5.15 | Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. ( Bjelic-Radisic, V; Dubsky, P; Fesl, C; Gnant, M; Greil, R; Königsberg, R; Marth, C; Mlineritsch, B; Pfeiler, G; Pöstlberger, S; Samonigg, H; Seifert, M; Singer, CF; Steger, GG; Stoeger, H; Taucher, S, 2011) |
| "Whether anastrozole has superior effects to tamoxifen for breast cancer remains controversial." | 4.95 | A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer. ( Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y, 2017) |
| "Recent trials have indicated that the aromatase inhibitors (anastrozole, letrozole, exemestane) are more effective than tamoxifen, the standard adjuvant treatment for estrogen receptor-positive breast cancer, both in adjuvant and first-line advanced settings." | 4.82 | Anastrozole. ( Cuzick, J, 2005) |
| "Growth velocity decreased and gynecomastia diminished during anastrozole treatment." | 3.79 | Management of prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy. ( Cataldo, C; D'Andrea, F; De Francesco, F; del Giudice, EM; Di Grezia, G; Ferraro, GA; Gatta, G; Grandone, A; Nicoletti, G; Perrone, L; Romano, T, 2013) |
| "We report a case of recurrent hormone receptor-positive breast cancer with brain metastases that showed good response to vinorelbine(VNR)and anastrozole(ANA)." | 3.78 | [A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies]. ( Hikino, H; Koike, M; Mukai, T; Murata, Y, 2012) |
| "Anastrozole is a safe and tolerable drug especially used to suppress estrogen action." | 1.35 | Treatment of autonomous ovarian follicular cyst with long-term anastrozole therapy. ( Berberoglu, M; Bilir, P; Engiz, O; Ocal, G; Siklar, Z, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Y | 1 |
| Pan, W | 1 |
| Tang, X | 1 |
| Wu, S | 1 |
| Sun, X | 1 |
| Ferraro, GA | 1 |
| Romano, T | 1 |
| De Francesco, F | 1 |
| Grandone, A | 1 |
| D'Andrea, F | 1 |
| del Giudice, EM | 1 |
| Cataldo, C | 1 |
| Gatta, G | 1 |
| Di Grezia, G | 1 |
| Perrone, L | 1 |
| Nicoletti, G | 1 |
| Sakurai, T | 2 |
| Umemura, T | 1 |
| Jinta, E | 1 |
| Suzuma, T | 1 |
| Yoshimura, G | 1 |
| Shimizu, S | 1 |
| Glück, S | 1 |
| Engiz, O | 1 |
| Berberoglu, M | 1 |
| Siklar, Z | 1 |
| Bilir, P | 1 |
| Ocal, G | 1 |
| Dunbier, AK | 1 |
| Anderson, H | 1 |
| Ghazoui, Z | 2 |
| Salter, J | 1 |
| Parker, JS | 1 |
| Perou, CM | 1 |
| Smith, IE | 1 |
| Dowsett, M | 2 |
| Martin, LA | 1 |
| Weigel, MT | 1 |
| Pancholi, S | 1 |
| Dunbier, A | 1 |
| Johnston, S | 1 |
| Pfeiler, G | 1 |
| Königsberg, R | 1 |
| Fesl, C | 1 |
| Mlineritsch, B | 1 |
| Stoeger, H | 1 |
| Singer, CF | 1 |
| Pöstlberger, S | 1 |
| Steger, GG | 1 |
| Seifert, M | 1 |
| Dubsky, P | 1 |
| Taucher, S | 1 |
| Samonigg, H | 1 |
| Bjelic-Radisic, V | 1 |
| Greil, R | 1 |
| Marth, C | 1 |
| Gnant, M | 1 |
| Bergh, J | 1 |
| Jönsson, PE | 1 |
| Lidbrink, EK | 1 |
| Trudeau, M | 1 |
| Eiermann, W | 1 |
| Brattström, D | 1 |
| Lindemann, JP | 1 |
| Wiklund, F | 1 |
| Henriksson, R | 1 |
| Mukai, T | 1 |
| Hikino, H | 1 |
| Koike, M | 1 |
| Murata, Y | 1 |
| Magee, PJ | 1 |
| Rowland, I | 1 |
| Cuzick, J | 2 |
| Buzdar, AU | 1 |
| Guastalla, JP | 1 |
| Nabholtz, JM | 1 |
| Lin, NU | 1 |
| Winer, EP | 1 |
| Takayama, K | 1 |
| Zeitoun, K | 1 |
| Gunby, RT | 1 |
| Sasano, H | 1 |
| Carr, BR | 1 |
| Bulun, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)[NCT00295646] | Phase 3 | 1,803 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for anastrozole and Recrudescence
| Article | Year |
|---|---|
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized | 2017 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormona | 2010 |
Soy products in the management of breast cancer.
Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-45 | 2012 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, | 2005 |
2 trials available for anastrozole and Recrudescence
| Article | Year |
|---|---|
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast | 2012 |
9 other studies available for anastrozole and Recrudescence
| Article | Year |
|---|---|
Management of prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: from aromatase inhibitors to subcutaneous mastectomy.
Topics: Adrenal Glands; Anastrozole; Aromatase Inhibitors; Child; Combined Modality Therapy; Comorbidity; Di | 2013 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2009 |
Treatment of autonomous ovarian follicular cyst with long-term anastrozole therapy.
Topics: Anastrozole; Aromatase Inhibitors; Child; Female; Humans; Nitriles; Ovarian Cysts; Puberty, Precocio | 2009 |
Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; | 2011 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast | 2011 |
[A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Fema | 2012 |
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Optimal use of aromatase inhibitors: to lead or to follow?
Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-F | 2007 |
Treatment of severe postmenopausal endometriosis with an aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Biopsy; Endometriosis; | 1998 |